DM: Prevention and Treatment of Cardiovascular Disease (2001)

Citation:
 
Study Design:
Class:
- Click here for explanation of classification scheme.
Quality Rating:
Research Purpose:

The primary objective of this study was to compare the cost-effectiveness of a cholesterol lowering protocol implemented by RDs with that of cholesterol lowering advice given by physicians in a clinical ambulatory setting. 

Inclusion Criteria:

1. 21-65 years of age

2. Total serum cholesterol: >5.2 mmol/L <8.84 mmol/L
Exclusion Criteria:

1. 2° medical conditions that would influence lipid levels: (pregnancy, perimenopausal condition, diabetes, thyroid disease or renal failure).

2. Use of medications that would alter lipids: hypolipidemic meds, thiazide diuretics, beta-blockers or estrogen replacement therapy.

3. Hypertriglyceridemia: >4.52 mmol/L

4. MNT for hypercholesterolemia in the past year.

Description of Study Protocol:

Recruitment:  Potential study candidates included 1,493 adults identified through the Massachusetts General Hospital (MGH) Clinical Laboratory Information Center.  13 primary care physicians who agreed to participate in this study enrolled 90 of their patients as study volunteers between June 1996 and April 1997.

Design

  • Study volunteers were randomly assigned to receive either MNT or usual care (UC) from physicians
  • MNT: cholesterol-lowering nutrition counseling using NCEP guidelines for a minimum of 2-3 visits over 2-3 months
  • MNT: If serum lipids were not in target range after 2-3 months, 2-3 additional RD visits were provided over the next 3 months.
  • UC: advice from physician but not RD
  • After 6 months lipid lowering medications and additional MNT could be added at the discretion of the physician for the UC study group.

Blinding Used (if applicable):

Lab tests.  Nutrition interviewers were masked to treatment assignment.

Intervention (if applicable):

Randomly assigned to receive MNT from RDs or usual care from physicians using permuted block randomization.

Statistical Analysis

  • Analysis of covariance controlling for baseline value of the variable and gender was used to asssess group differences in the change in dietary intake and lipid levels at 3 months, 6 months, and 1 year.
  • baseline comparisons made using t tests for continuous variables and fisher's exact test for categorical variables
  • within group changes were calculated using paired t tests
  • Pearson product moment correlations were coputed to correlate dietary intake and clinical outcomes
  • Wilcoxon test used to compare differences in patient satisfaction between groups at baseline and 6 months

 

 

Data Collection Summary:

Timing of Measurements:  Baseline, 6 months, 1 year, and 6 months after the end of the study intervention. 

  • Body weight and height, fasting plasma lipids: 0, 3, 6 months and 1 year;
  • Diet analysis: 0, 3, 6, months and 1 year using 24-hour recall
  • Patient Satisfaction Survey: 0, and 6 months; subjects reported physical activity.

Dependent Variables

  • Weight
  • Fasting plasma lipid profiles
  • Dietary intake of fat and cholesterol, based on random 24-hour recalls
  • Patient Satisfaction, survey adapted from the Diabetes Quality of Life measure for the DCCT 

 Independent Variables

  • Total RD time with patients
  • Cost Outcomes, according to the standard charges at the Massachussetts General Hospital using Transition Systems Inc data from 1995 and changes in the consumer price index for medical care services for urban consumers betwee 1995 and 1997

Control Variables

  • baseline values
  • gender

 

Description of Actual Data Sample:

Initial N:  90 (60 men and 30 women)

Attrition (Final N): 88.  One man from each study group dropped out of the study. There was no difference in demographic characteristics of subjects by study group at baseline.

Age, Ethnicity, Other Relevant Demographics, and Anthropometrics

   

MNT Group

UC group

Age, y

49±10

49±11

BMI

27±4

28±4

Male sex, %

67

67

Caucasian, %

93

96

Income  > $40,000, %

84

80

College Graduate, %

82

67

Smoker, %     11         4

 Location:  Boston MA

Summary of Results:

Outcomes at 6 months

  MNT Usual Care
Kcals 1679± 796 1850± 675
% fat 25± 10** 29 ±10
% sat fat 7 ±4*** 10 ±4
% MUFA 9± 4** 11± 4
%PUFA 7 ±4 5 ±2
Cholesterol,  mg 165 ±132* 239 ±199
Dietary fiber, g 18 ±8 16 ±6
Serum cholesterol, mmol/l 5.77± 0.60* 6.03 ±.065
LDL, mmol/l 3.98± 0.55 4.13 ±0.60
HDL, mmol/l 1.14 ±0.36 1.09± 0.31
Trig, mmol/l 1.47 ±0.73 1.85 ±1.27
Weight, kg 77.7 ±15.4*** 83.2 ±15.0

Activity, minutes per week

144 ±130

108 ±109

*P<0.05    **P<0.001     ***P<0.001

MNT counseling time:

RDs spent an average of 90 minutes (60-140 minutes)/subject or an average of 2.5+0.5 visits in the first 3 months and 30 minutes /subject (1.5+0.8 visits) in the second 3 months.

The time spent with the RD by month 3 was correlated with decrease in serum total cholesterol (r= -0.47, P=0.001) and LDL-cholesterol (r= -0.39, P=0.008) and with weight reduction (r= -0.34, P=0.02).

Cost Outcomes:

The additional costs of MNT were $217/patient to achieve a 6% decrease in cholesterol and an additional $98/patient to sustain the decrease.

The cost effectiveness of MNT was $36 per 1% decrease.

Patient Satisfaction:

At baseline there were no differences between study groups. At 6 months, the MNT group reported significantly increased satisfaction levels with clinic visits, dietitians’ vs. physicians' understanding of lifestyle and eating habits, their knowledge about cholesterol, ability to manage cholesterol levels, and eating habits than the UC group. Satisfaction scores were significantly different (P<0.001).

Author Conclusion:

Dietitians can use these research results with physicians, third-party payers, and decision makers in health systems to substantiate the effectiveness of MNT in decreasing fat intake and decreasing serum cholesterol. The greater patient satisfaction that occurred with MNT provides evidence that the quality counseling process is also important.

The significant improvement in all of these outcomes provides evidence that MNT is a reasonable investment of healthcare resources and supports our recommendation that NCEP dietary guidelines should be implemented by RD as much as possible and in an ongoing manner to achieve and sustain maximum health benefits.

MNT by an RD is a reasonable investment of resources because it results in significantly better lipid, diet, activity, weight, and patient satisfaction outcomes than UC.
Funding Source:
University/Hospital: Massachusetts General Hospital
Reviewer Comments:
Very nice study with good design. The length of this study was good (1 year), however the protocol for the UC group changed for the second 6 months so the differences in LDL cholesterol were no longer significant at 1 year. Even though the differences between groups were statistically significant for some parameters (weight, LDL cholesterol, % SF in diet), the differences were quite small.
Quality Criteria Checklist: Primary Research
Relevance Questions
  1. Would implementing the studied intervention or procedure (if found successful) result in improved outcomes for the patients/clients/population group? (Not Applicable for some epidemiological studies) Yes
  2. Did the authors study an outcome (dependent variable) or topic that the patients/clients/population group would care about? Yes
  3. Is the focus of the intervention or procedure (independent variable) or topic of study a common issue of concern to dieteticspractice? Yes
  4. Is the intervention or procedure feasible? (NA for some epidemiological studies) Yes
 
Validity Questions
1. Was the research question clearly stated? Yes
  1.1. Was (were) the specific intervention(s) or procedure(s) [independent variable(s)] identified? Yes
  1.2. Was (were) the outcome(s) [dependent variable(s)] clearly indicated? Yes
  1.3. Were the target population and setting specified? Yes
2. Was the selection of study subjects/patients free from bias? Yes
  2.1. Were inclusion/exclusion criteria specified (e.g., risk, point in disease progression, diagnostic or prognosis criteria), and with sufficient detail and without omitting criteria critical to the study? Yes
  2.2. Were criteria applied equally to all study groups? Yes
  2.3. Were health, demographics, and other characteristics of subjects described? Yes
  2.4. Were the subjects/patients a representative sample of the relevant population? Yes
3. Were study groups comparable? Yes
  3.1. Was the method of assigning subjects/patients to groups described and unbiased? (Method of randomization identified if RCT) Yes
  3.2. Were distribution of disease status, prognostic factors, and other factors (e.g., demographics) similar across study groups at baseline? Yes
  3.3. Were concurrent controls or comparisons used? (Concurrent preferred over historical control or comparison groups.) Yes
  3.4. If cohort study or cross-sectional study, were groups comparable on important confounding factors and/or were preexisting differences accounted for by using appropriate adjustments in statistical analysis? N/A
  3.5. If case control study, were potential confounding factors comparable for cases and controls? (If case series or trial with subjects serving as own control, this criterion is not applicable.) N/A
  3.6. If diagnostic test, was there an independent blind comparison with an appropriate reference standard (e.g., "gold standard")? N/A
4. Was method of handling withdrawals described? Yes
  4.1. Were follow-up methods described and the same for all groups? Yes
  4.2. Was the number, characteristics of withdrawals (i.e., dropouts, lost to follow up, attrition rate) and/or response rate (cross-sectional studies) described for each group? (Follow up goal for a strong study is 80%.) Yes
  4.3. Were all enrolled subjects/patients (in the original sample) accounted for? Yes
  4.4. Were reasons for withdrawals similar across groups? ???
  4.5. If diagnostic test, was decision to perform reference test not dependent on results of test under study? N/A
5. Was blinding used to prevent introduction of bias? Yes
  5.1. In intervention study, were subjects, clinicians/practitioners, and investigators blinded to treatment group, as appropriate? No
  5.2. Were data collectors blinded for outcomes assessment? (If outcome is measured using an objective test, such as a lab value, this criterion is assumed to be met.) Yes
  5.3. In cohort study or cross-sectional study, were measurements of outcomes and risk factors blinded? N/A
  5.4. In case control study, was case definition explicit and case ascertainment not influenced by exposure status? N/A
  5.5. In diagnostic study, were test results blinded to patient history and other test results? N/A
6. Were intervention/therapeutic regimens/exposure factor or procedure and any comparison(s) described in detail? Were interveningfactors described? Yes
  6.1. In RCT or other intervention trial, were protocols described for all regimens studied? Yes
  6.2. In observational study, were interventions, study settings, and clinicians/provider described? N/A
  6.3. Was the intensity and duration of the intervention or exposure factor sufficient to produce a meaningful effect? Yes
  6.4. Was the amount of exposure and, if relevant, subject/patient compliance measured? Yes
  6.5. Were co-interventions (e.g., ancillary treatments, other therapies) described? N/A
  6.6. Were extra or unplanned treatments described? N/A
  6.7. Was the information for 6.4, 6.5, and 6.6 assessed the same way for all groups? Yes
  6.8. In diagnostic study, were details of test administration and replication sufficient? N/A
7. Were outcomes clearly defined and the measurements valid and reliable? Yes
  7.1. Were primary and secondary endpoints described and relevant to the question? Yes
  7.2. Were nutrition measures appropriate to question and outcomes of concern? Yes
  7.3. Was the period of follow-up long enough for important outcome(s) to occur? Yes
  7.4. Were the observations and measurements based on standard, valid, and reliable data collection instruments/tests/procedures? Yes
  7.5. Was the measurement of effect at an appropriate level of precision? Yes
  7.6. Were other factors accounted for (measured) that could affect outcomes? Yes
  7.7. Were the measurements conducted consistently across groups? Yes
8. Was the statistical analysis appropriate for the study design and type of outcome indicators? Yes
  8.1. Were statistical analyses adequately described and the results reported appropriately? Yes
  8.2. Were correct statistical tests used and assumptions of test not violated? Yes
  8.3. Were statistics reported with levels of significance and/or confidence intervals? Yes
  8.4. Was "intent to treat" analysis of outcomes done (and as appropriate, was there an analysis of outcomes for those maximally exposed or a dose-response analysis)? Yes
  8.5. Were adequate adjustments made for effects of confounding factors that might have affected the outcomes (e.g., multivariate analyses)? Yes
  8.6. Was clinical significance as well as statistical significance reported? Yes
  8.7. If negative findings, was a power calculation reported to address type 2 error? N/A
9. Are conclusions supported by results with biases and limitations taken into consideration? Yes
  9.1. Is there a discussion of findings? Yes
  9.2. Are biases and study limitations identified and discussed? No
10. Is bias due to study's funding or sponsorship unlikely? Yes
  10.1. Were sources of funding and investigators' affiliations described? Yes
  10.2. Was the study free from apparent conflict of interest? Yes